About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Quality of Life Benefits Through Prospective Neurotoxicity Assessment in Patients With Cancer: Insights From the NTox-PARTICIPATE Study.

Researchers

Stefanie Hartinger, Julia Bechwar, Niklas A Leistner, Matthias Mäurer, Olaposi Yomade, Nathan Page, Sophia K J Fischer, Max Grünstein, Clemens Risse, Nico Andreas, Benjamin Vlad, Ute Neugebauer, Jürgen Popp, Thomas E Mayer, Thomas Ernst, Ulf Schnetzke, Claudia Feder, Susanne M Lang, Steven Goetze, Stefan Brodoehl, Matthias Gawlitza, Marc-Oliver Grimm, Orlando Guntinas-Lichius, Dirk O Bauerschlag, Stefanie Deinhardt-Emmer, Thomas Lehmann, Matthias Schwab, Christian Senft, Irina Mäurer

Abstract

Neurologic adverse events associated with oncological immunotherapies, including CAR T-cell therapy and immune checkpoint inhibitors, are becoming increasingly prevalent. The NTox-PARTICIPATE trial was designed to characterize the neurologic effects of CAR T-cell therapy and checkpoint inhibitors (target group) compared with other systemic treatments (control group), while incorporating a study-specific questionnaire to assess feasibility and patient-perceived impact of study procedures. The NTox-PARTICIPATE trial is a single-center prospective pilot study integrating longitudinal neurologic assessments, magnetic resonance imaging, neuromuscular ultrasound, and blood-based immunomonitoring into oncological care. This analysis focuses on patient-reported experiences collected through a study-specific survey assessing satisfaction with study procedures, organizational burden, communication, and the perceived benefit of study participation. Patients were eligible for survey participation after completion of at least 3 study visits. Data were analyzed using the Wilcoxon signed-rank test for paired ordinal data and the McNemar test for paired binary data. Of 75 enrolled patients, 56 received the survey based on the eligibility criteria and 50 returned completed questionnaires. Patients reported high satisfaction with organizational aspects, communication, response times, counseling on premorbidities and new neurologic conditions, as well as interdisciplinary collaboration (medians +3; 25th percentile +1 or +2, 75th percentile +3). In total, 94% of participants reported increased awareness of newly occurring neurologic symptoms. Notably, 74% of participants perceived an improvement in quality of life through study participation, and 94% expressed willingness to participate again and to recommend the study to others. Longitudinal neurologic monitoring within the NTox-PARTICIPATE framework was feasible and well accepted by patients with cancer. Despite additional organizational effort, patients reported high satisfaction, increased awareness of neurologic symptoms, and improved perceived quality of care attributed to study participation. Integrating patient perspectives alongside structured neurologic assessments may support earlier detection of neurotoxicity, individualized management strategies, and future patient-centered trial design. The study is registered at German Register of Clinical Trials under the identification number DRKS00032520. The approval number of the ethics committee for this study is 2023-3023-BO.
Source: PubMed (PMID: 43038500)View Original on PubMed